Roche and Celgene set for battle in acute myelogenous leukaemia

Roche and Celgene set for battle in acute myelogenous leukaemia

Source: 
EP Vantage
snippet: 

Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.